Explore all 16 agreements struck thus far between pharmaceutical companies and the White House to adhere to most favored nation pricing for drugs sold in the United States.
Most favored nation (MFN), the pricing approach where a country’s drugs are priced at the lowest comparable amount from in any other developed nation, is being rapidly employed in the United States. The White House has sought out voluntary agreements with dozens of pharmaceutical companies to ensure compliance with MFN principles and attempt to lower drug prices for American consumers. These deals could turn the pharmaceutical industry on its head.
“These initiatives could change what patients pay and how pharmacies operate,” according to Ned Milenkovich, PharmD, JD, principal at Much Shelist, P.C. and member of the Pharmacy Times Editorial Advisory Board, in an interview.
In this article, you will find a round-up of all 16 agreements between biopharmaceutical companies and the White House in chronological order, along with relevant details and medications impacted, if available. You can read more detailed insights about the MFN program from Ned Milenkovich
Representatives from Pfizer were the first to
The specific terms of the agreement—including the drugs that will be included on the TrumpRx purchasing platform—have yet to be revealed.1
AstraZeneca announced an agreement with the Trump Administration to provide DTC sales of prescriptions for chronic diseases to eligible patients at 80% off list prices. The company will also participate in TrumpRx.2
As part of the agreement, the US Department of Commerce will delay Section 232 tariffs for 3 years. AstraZeneca announced their intention to fully onshore medicines manufacturing to ensure that medicines sold in America are made in the country.2
EMD Serono announced that they had voluntarily agreed to expand access to the company’s portfolio of in vitro fertilization (IVF) therapies. The company will offer DTC sales of its full portfolio of IVF therapies, including follitropin alfa injection (Gonal-f), choriogonadotropin alfa injection (Ovidrel), and cetrorelix acetate for injection (Cetrotide) to patients with prescriptions at significantly reduced prices. When all 3 therapies are used together in a typical IVF protocol, the company expects patients to receive an 84% discount off list prices.3
Section 232 tariffs will be delayed, provided EMD Serono continues to invest in biopharmaceutical manufacturing in the United States.3
Eli Lilly’s agreement with the Trump Administration is perhaps the most detailed. As part of the deal, Medicare beneficiaries will pay no more than $50 per month for tirzepatide (Zepbound) or orforglipron upon its approval from the FDA.4
Lilly will also expand their DTC offerings through LillyDirect. The company plans to offer a tirzepatide multidose pen at $299 for the lowest available dose, with further doses up to $449, accounting for a $50 discount to current prices. When a patient refills their prescription through LillyDirect, they will pay no more than $449. Additionally, orforglipron will have the lowest dose available starting at $149, with additional doses priced up to $399.4
Novo Nordisk centered their announcement around their blockbuster weight loss drug, semaglutide. By expanding access through TrumpRx, Novo Nordisk will offer semaglutide at reduced prices to Medicare Part D and Medicaid patients. Coverage of the anti-obesity medicines for those on Medicare Part D will be enabled through a pilot program, which is expected to cover most Part D beneficiaries.5
Amgen announced the expansion of their AmgenNow DTC program to include erenumab-aooe (Aimovig) and adalimumab-aato (Amjevita), which are self-administered injectable monoclonal antibody therapies. Erenumab-aooe is designed for migraine prevention, while adalimumab-aato is a biosimilar to treat various autoimmune disorders.6
The drugs will be available at a discounted monthly price of $299, which is nearly 60% and 80% lower than their respective list prices. The company will feature these drugs, including evolocumab (Repatha), on TrumpRx.gov.6
Boehringer Ingelheim provided little specifics in their announcement of their MFN agreement with the Trump Administration. Broadly, the company agreed to lower the cost of medicines for American patients and participate in TrumpRx.gov. The company also announced an investment of $10 billion through 2028 to expand pharmaceutical research and development in the United States.7
A centerpiece to Bristol Myers Squibb’s (BMS) agreement with the US government was apixaban (Eliquis), a common prescription anticoagulant designed to prevent and treat blood clots. BMS said that they will provide apixaban for free to recipients of Medicaid, while donating over 7 tons of apixaban’s active pharmaceutical ingredient to the United States.8
In addition, BMS announced new DTC access to key medications for cash-paying patients, including deucravacitinib (Sotyktu), ozanimod (Zeposia), atazanavir (Reyataz), entecavir (Baraclude), and abatacept (Orencia SC). This would lower prices by approximately 80% compared with current list prices, according to the announcement.8
Genentech committed to lowering drug costs for patients on state Medicaid programs, along with offering many of the company’s medications for serious diseases at prices comparable to those available in other wealthy countries, a key tenant of MFN.9
The company also announced their intention to expand their recently launched DTC program for its portfolio of critical influenza medicines. The program will also be available through TrumpRx.gov.9
In their announcement, Gilead Sciences said they had adhered to President Trump’s executive order by offering discounts on certain existing medicines within Medicaid to ensure they are priced like amounts on other developed nations. These include select medications for HIV, hepatitis B, hepatitis C, and COVID-19.10
Gilead is also launching a DTC program where patients can purchase sofosbuvir/velpatasvir (Epclusa), a hepatitis C treatment and cure, at a discounted cash price. The drug will also be offered on TrumpRx.gov.10
GSK entered into a voluntary agreement with the US government following the adherence of each of President Trump’s demands outlined in his May 2025 executive order. The company said that they will lower prices of drugs in their respiratory portfolio for patients enrolled in Medicaid, such as medicines for conditions like asthma or chronic obstructive pulmonary disease.11
Along with launching new products at MFN pricing, GSK also intends to make most of its inhaled respiratory portfolio available to patients on a DTC platform that will offer savings of up to 66%. GSK will help bolster the US supply chain by donating a reserve of albuterol to the country’s Strategic Active Pharmaceutical Ingredients Reserve.11
As part of their agreement with the Trump Administration, Merck will provide key products from their pipeline in a DTC program, including offering sitagliptin (Januvia), sitagliptin/metformin (Janumet), and Janumet extended-release tablets at discounts of up to 70%. This program is expanded to include enlicitide decanoate, an oral cholesterol-lowering drug, following its expected approval.12
Novartis announced that future medications launched by the company will be offered at MFN pricing. Furthermore, the company will build a DTC platform for siponimod (Mayzent), midostaurin (Rydapt), and capmatinib (Tabrecta). The drugs will also be available through TrumpRx.13
Furthermore, the company is applying to participate in the Generating Cost Reductions for US Medicaid Model, which is aimed at further improving access to medicines for patients in the US on Medicaid.13
The agreement reached between Sanofi and the US government will ensure MFN pricing for Sanofi medicines, reducing prices by an average of 61% for medicines that treat diabetes, cardiovascular and neurological conditions, and cancer.14
Consumers will have access to lower-cost medications through the TrumpRx purchasing platform, and along with other DTC platforms, patients can expect an average savings of nearly 70% for certain medications for infections and diabetic conditions.14
Officials from Johnson & Johnson announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for Americans. The company will participate in the DTC TrumpRx platform, allowing for significantly discounted medication prices. The agreement will also facilitate MFN pricing for Medicaid recipients.15
AbbVie intends to expand DTC offerings through the TrumpRx purchasing platform while pledging $100 billion in US-based research and development, including manufacturing. Drugs that will be featured in AbbVie’s DTC program and TrumpRx include brimonidine tartrate (Alphagan), brimonidine tartrate/timolol maleate (Combigan), adalimumab (Humira), and levothyroxine sodium (Synthroid).16
The agreement also grants AbbVie a grace period from tariffs and future price mandates.16
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
